Market Overview

UPDATE: Piper Jaffray Reiterates Overweight on Globus Medical on Synthes Award in Line With Expectations

Globus Medical Finds Support At $26 Area Again
Globus Medical's FY16 Sales Guidance Tempers Q4, FY15 Above-The-Street Outlook

In a report published on Monday, Piper Jaffray analyst Matt Miksic reiterated an Overweight rating on Globus Medical (NYSE: GMED) and maintained a $22 price target on the company.

In the report, Piper Jaffray commented that, "The jury award related to the Synthes patent case was roughly in line with expectations, given the revenue history of the products in question and royalty rate in the 8-15% range. The implied royalty in the jury award hit the high end of the range (15%) by historical standards, but not inconsistent with the recent ongoing royalty rates set for certain products related to the NuVasive-Medtronic jury award (13.75%). Globus has stated that it will seek the reversal of this decision through post-trial motions or the appeals process, however if the award ultimately stands as is, we believe it would represent another efficient resolution of patent litigation by management in a manner that minimizes disruption to the business, while also preserves capital and avoids the downstream impact of ongoing royalties. We reiterate our Overweight rating on GMED and $22 target, and remain buyers at current levels."

Globus Medical closed on Friday at $15.19.

Latest Ratings for GMED

Jan 2016Bank of AmericaDowngradesBuyUnderperform
Oct 2015Leerink SwannMaintainsOutperform
Sep 2015Morgan StanleyInitiates Coverage onOverweight

View More Analyst Ratings for GMED
View the Latest Analyst Ratings

Posted-In: Matt Miksic Piper JaffrayAnalyst Color Reiteration Analyst Ratings


Related Articles (GMED)

Get Benzinga's Newsletters